ALNYLAM PHARMACEUTICALS, INC. (25)

Browse by Contract Category

Contracts

Employment Agreement effective as of August 2, 2021 between the Company and John M. Maraganore, Ph.D (Filed With SEC on August 3, 2021)
Supplemental Agreement effective July 27, 2009 by and among the (Filed With SEC on August 3, 2021)
Second Amendment to Lease entered into as of April 28, 2021 by and between BMR-Fresh Pond Research Park LLC and the Registrant (Filed With SEC on August 3, 2021)
Purchase and Sale Agreement dated April 10, 2020 between BX Bodyguard Royalties L.P. and the Registrant (Filed With SEC on August 6, 2020)
Amendment to License and Collaboration Agreement, dated as of November 22, 2019 between the Registrant and The Medicines Company (Filed With SEC on February 13, 2020)
Amended and Restated ALN-AT3 Global License Terms entered into as of April 8, 2019 by and between the Registrant and Genzyme Corporation (Filed With SEC on August 6, 2019)
Amendment No. 1 to Sponsored Research Agreement dated as of July 27, 2009 (Filed With SEC on August 3, 2021)
Sponsored Research Agreement dated as of July 27, 2009 by and among the (Filed With SEC on August 3, 2021)
Change in Control Agreement dated November 2, 2020 by and between the Registrant and John M. Maraganore (Filed With SEC on February 11, 2021)
Amended and Restated Annual Incentive Program, as amended (Filed With SEC on February 11, 2021)
Letter Agreement between the Registrant and Barry E. Greene dated August 26, 2020 (Filed With SEC on November 5, 2020)
First Amendment to Lease entered into between the Registrant and RREEF America REIT II CORP. PPP dated September 30, 2020 (Filed With SEC on November 5, 2020)
First Amendment to (Filed With SEC on November 5, 2020)
Co-Development Agreement between the Registrant and BXLS (Filed With SEC on November 5, 2020)
Patent Cross-License Agreement dated April 3, 2020 between Dicerna Pharmaceuticals, Inc. and the Registrant (Filed With SEC on August 6, 2020)
Amended and Restated Annual Incentive Program (Filed With SEC on February 13, 2020)
Description of Capital Stock (Filed With SEC on February 13, 2020)
Amended and Restated Investor Agreement dated as of April 8, 2019 by and between the Registrant and Genzyme Corporation (Filed With SEC on August 6, 2019)
Investor Agreement dated as of April 8, 2019 by and between the Registrant and Regeneron Pharmaceuticals, Inc (Filed With SEC on August 6, 2019)
Stock Purchase Agreement dated as of April 8, 2019 by and between the Registrant and Regeneron Pharmaceuticals, Inc (Filed With SEC on August 6, 2019)
Amendment No. 3 entered into as of April 8, 2019 to the Master Collaboration Agreement dated as of January 11, 2014, as amended by Amendment No. 1 and Amendment No. 2, including... (Filed With SEC on August 6, 2019)
Form of Ex-US Restricted/Performance Stock Unit Award Agreement under 2018 Stock Incentive Plan, as amended (Filed With SEC on August 6, 2019)
2018 Stock Incentive Plan, as amended (Filed With SEC on August 6, 2019)
Amended and Restated 2004 Employee Stock Purchase Plan, as amended (Filed With SEC on May 2, 2019)
Underwriting Agreement, dated January 14, 2019, between Alnylam Pharmaceuticals, Inc. and Barclays Capital Inc (Filed With SEC on January 15, 2019)